Table 2.

Univariate analysis of included variables on cancer-specific survival

Variable	Training cohort (n = 10,612)			Validation cohort (n = 4548)
	HR	95% CI	P	HR	95% CI	P
Tumor sizea	1.003	1.003–1.003	< 0.001	1.003	1.002–1.003	< 0.001
LONTa	0.255	0.24–0.272	< 0.001	0.276	0.252–0.302	< 0.001
NLNsa	0.965	0.961–0.968	< 0.001	0.966	0.961–0.971	< 0.001
Age(ref =  > 60)	0.873	0.817–0.932	< 0.001	0.855	0.772–0.946	0.002
Sex (ref = male)	0.936	0.880–0.995	0.035	0.941	0.857–1.034	0.205
TNM (ref = stage III)			< 0.001			< 0.001
I	0.149	0.135–0.164	< 0.001	0.160	0.139–0.185	< 0.001
II	0.411	0.384–0.439	< 0.001	0.475	0.429–0.526	< 0.001
T stage ( ref = T4b)			< 0.001			< 0.001
T1	0.129	0.112–0.148	< 0.001	0.136	0.108–0.171	< 0.001
T2	0.255	0.222–0.293	< 0.001	0.268	0.215–0.334	< 0.001
T3	0.533	0.478–0.594	< 0.001	0.567	0.473–0.681	< 0.001
T4a	0.830	0.741–0.931	< 0.001	0.858	0.709–1.039	0.116
N stage ( ref= N3b)			< 0.001			< 0.001
N0	0.145	0.130–0.162	< 0.001	0.157	0.133–0.187	< 0.001
N1	0.330	0.295–0.370	< 0.001	0.375	0.315–0.446	< 0.001
N2	0.474	0.424–0.530	< 0.001	0.480	0.404–0.570	< 0.001
N3a	0.666	0.596–0.744	< 0.001	0.772	0.651–0.915	0.003
Differentiation (ref = G3 + G4)
G1	0.368	0.308–0.441	< 0.001	0.455	0.354–0.586	< 0.001
G2	0.603	0.562–0.646	< 0.001	0.671	0.606–0.744	< 0.001
Histology(ref = adenocarcinoma)	1.281	1.198–1.369	< 0.001	1.196	1.079–1.325	0.001
Location (ref = cardiac)
Middleb	0.742	0.685–0.804	< 0.001	0.822	0.731–0.924	0.001
Antrum/pylorus	0.833	0.772–0.898	< 0.001	0.757	0.673–0.851	< 0.001
Other	1.092	0.994–1.201	0.067	0.968	0.835–1.121	0.661
Race (ref = others)			< 0.001			< 0.001
White	1.359	1.258–1.467	< 0.001	1.364	1.211–1.536	< 0.001
Black	1.348	1.213–1.498	< 0.001	1.398	1.190–1.643	< 0.001

CI Confidence interval, HR Hazard ratio, LONT Log odds of negative lymph nodes/T stage, NLNs negative lymph nodes, ref Reference

^aThese variables were treated as continuous data

^bThe location included the body, fundus, greater curvature and lesser curvature of the stomach.